Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07064122 · ClinicalTrials.gov registry record · Phase 1
A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)
A Phase 1 study of Haematologic Neoplasms, sponsored by AstraZeneca.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 72
- Enrollment target
- 20
- Study locations
NCT07064122: Recruiting Phase 1 study of Haematologic Neoplasms, sponsored by AstraZeneca.
NCT07064122 is a Phase 1 study of Haematologic Neoplasms that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 72 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07064122, a Phase 1 study of Haematologic Neoplasms, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 72 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.
Primary Outcome
A DLT is defined as an adverse event or abnormal laboratory value occurring during the DLT-evaluation period (first 28 days of treatment). This will be evaluated to assess the safety and tolerability and also to identify optimal biological dose (OBD) of AZD2962.
Conditions Studied
Interventions
- DRUG AZD2962
Study Locations (20)
Other
- Research Site - Heidelberg
- Research Site - Melbourne
- Research Site - Shinagawa-ku
- Research Site - Yoshida-gun
- Research Site - Seoul
- Research Site - Seoul
- Research Site - Barcelona
- Research Site - Madrid
- Research Site - Madrid
- Research Site - Pamplona
- Research Site - Salamanca
- Research Site - Valencia
- Research Site - Kaohsiung City
- Research Site - Tainan
- Research Site - Taipei
- Research Site - London
- Research Site - London
Florida
- Research Site - Miami
- Research Site - Tampa
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2025-11-03 |
| Est. Completion | 2028-10-20 |
| Phase | Phase 1 |
What NCT07064122 shows while recruiting
NCT07064122 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (20% higher).
The record links to 1 condition, with Haematologic Neoplasms appearing as the primary indexed condition, and to 1 intervention - of which AZD2962 is the first listed.
NCT07064122 names 20 study sites across 3 states, led by Other, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT07064122 about?
NCT07064122 is a clinical study titled "A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers)". The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasm...
What is the current status of trial NCT07064122?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 72 participants. The study started on 2025-11-03. Estimated completion is 2028-10-20.
What conditions does trial NCT07064122 study?
This clinical trial studies the following conditions: Haematologic Neoplasms.
What interventions are being tested in trial NCT07064122?
The interventions under investigation include: AZD2962 (DRUG).
Who is sponsoring clinical trial NCT07064122?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07064122 being conducted?
This trial has 20 study locations across Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07064122's enrollment target sits among peer trials
72 736th of 2000 higher than 1,254 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI